Navigation Links
Avexa Reports Positive Phase IIb Result

VICTORIA, Australia--(BUSINESS WIRE)--Mar 20, 2007 - Australian biotechnology company Avexa (ASX:AVX) today announced highly successful results from its Phase IIb trial for apricitabine (ATC). ATC is Avexa's novel nucleoside reverse transcriptase inhibitor (NRTI) being developed for the treatment of HIV infection in patients with drug-resistant HIV.

The Phase IIb trial compared the effectiveness of ATC in reducing the viral load of patients with drug-resistant HIV with the effectiveness of lamivudine (3TC), a leading NRTI in widespread use. A total of 47 patients completed 21 day dosing. Of these 17 patients received 600 mg doses of ATC, 16 received 800 mg doses of ATC and the control group of 14 patients were treated with 3TC.

The results for patients in both ATC cohorts exceeded the Phase IIb trial primary endpoint by a substantial margin. Patients who received ATC achieved on average a reduction of greater than 0.8 log(10) (85%) in the level of HIV in the blood after 21 days treatment compared to a reduction of less than 0.03 log(10) in patients treated with 3TC. Nine patients achieved a greater than 1.5 log(10) (97%) reduction after 21 days, with 3 patients achieving a reduction of over 2.0 log(10) (99%). Remarkably, one patient achieved a decrease in the amount of virus of more than 2.5 log(10) (99.7%) after 21 days on ATC. Patients with the highest degree of drug resistance still achieved a significant benefit from treatment with ATC. The demonstration of superior activity in this study indicates that ATC will be an effective antiviral drug for the treatment of many drug-resistant patients, including even those most highly resistant.

"This is a fantastic result for Avexa," stated CEO Dr Julian Chick. "The positive result allows us to continue to progress ATC into Phase III trials and towards commercialisation. The team at Avexa has done a great job and these excellent results show that their
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avexas Apricitabine Clinical Trial Update
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Reports Positive Phase IIb Result
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2
... Oct. 15 ISTA Pharmaceuticals, Inc. (Nasdaq: ... 2010 financial results after market close on November 2, ... call at 4:30 p.m. Eastern Time focusing on its ... answer session after each set of formal comments.  Date: ...
... Oct. 15 Methodist Mansfield Medical Center will provide ... Independent School District as well as sponsor a Principals, ... and fitness. By helping principals and school personnel create ... Medical Center is creating a healthy environment for the ...
Cached Medicine Technology:Methodist Mansfield Medical Center Donates 4,000 Pedometers for Entire Mansfield ISD Staff 2
(Date:8/29/2014)... (PRWEB) August 29, 2014 Dr. Parsa Mohebi ... stages of hair loss achieve great results in hair transplantation. ... Facial Hair Transplant , an FUE method that harvests facial ... This method lets patients whose hair loss classification is ... Hair Transplant is a great alternative for those advanced hair ...
(Date:8/29/2014)... Mar, CA (PRWEB) August 29, 2014 A ... bra,” a bra developed by a Tokyo clothing store for ... in the hopes of rectifying or diminishing their problem. Board-certified ... treated men with the problem. While many people only associate ... actually a fairly common condition among men of all ages, ...
(Date:8/29/2014)... 29, 2014 Healthpointe is pleased ... Physical Therapy students via Clinical Rotations. ... be shadowing Healthpointe providers and specialists throughout their ... develop clinical experience and learn professional preparation. ... gain insight into several patient care techniques and ...
(Date:8/29/2014)... 2014 Highly regarded audiologist , Dr. Mary ... health topics. The four reports are titled:, , ... Hearing Aid Success , The Top 5 Things You ... Auditory Processing Disorder in Children , Dr. Mary Anne ... a lot of confusion and misinformation about each them. The ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2
... the genetic variations in detoxifying enzymes for developing Lou ... genetic variations in three enzymes, which are used to ... for metabolising cholesterol lowering, statin drugs might be a ... or Lou Gehrig's disease). The study also indicates that ...
... failing to implement rules that will reduce the risk ... instruments. ,The report said that surgical teams ... be traced easily. Instead kits are being swapped for ... executive of the NHS Confederation, said it was vital ...
... of health has expressed concern about the rise in the ... increase in the number of girls under the age of ... and depression. According to the Bureau of Health Promotion ... smoke regularly. , Deputy Director of the health ...
... NSW, daycare centers are planning to phase out junk food ... up by the Health Department to counter childhood obesity//. ... drinks, even as they were being sent to dieticians. ... two to five-year-olds, is the biggest study of its kind ...
... The Hyderabad-based Aurobindo Pharma Ltd today said it has ... Jersey//. ,The facility, spread over 20 acres of ... quarters, it informed the stock exchanges. ,"This purchase ... effective manner," Ramprasad Reddy, Chairman of the company, said. ...
... A 62-year-old child psychiatrist has become Britain’s oldest mother ... that Patti Farrant, professionally known as Patricia Rashbrook, gave ... born at the Royal Sussex County Hospital in Brighton, ... is already a mother to three grown-up children from ...
Cached Medicine News:Health News:Genetic Variations In Detoxifying Genes Lead To Lou Gehrig's diseases 2
... Immunoassay Plus Control is a ... in today's busy immunoassay laboratory. ... this human serum based control ... separate control products for immunoassay ...
... The Vidiera NsD Nucleic Sample Detection ... acids, post amplification. The new platform ... by capillary electrophoresis (CE), with software features ... and flexibility. Vidiera NsD has the ...
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... PLUS CONCENTRATOR ANALYZER Now there is one ... parameters necessary for performing concentrator checks. Introducing ... efficient and cost-effective analyzer designed with technicians ... flow rate (L-min), and patient outlet pressure ...
Medicine Products: